Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days for obtaining a report for the IgVH Gene Mutation Test is 14 days.

What are the prerequisites for the test IgVH Gene Mutation Test

  • Patients must have a confirmed diagnosis of chronic lymphocytic leukemia (CLL)
  • Patients must have a suitable sample of blood or bone marrow available for testing
  • Patients must not have any contraindications to undergoing a genetic test
  • Patients must have provided informed consent for the test

What are the measure values for the test IgVH Gene Mutation Test

  • Positive: ≥ 98% homology to germline gene sequence
  • Intermediate: 95-97% homology to germline gene sequence
  • Negative: < 95% homology to germline gene sequence

What does this test IgVH Gene Mutation Test identify?

  • This test identifies the mutation status of the Immunoglobulin Variable Region Heavy Chain (IgVH) gene in B-cell lymphomas.
  • It helps determine the clonality and maturity of the B-cell population, which can be useful for prognosis and treatment decisions.
  • Patients with mutated IgVH genes tend to have a better prognosis compared to those with unmutated genes.
  • The test can also be used to monitor disease progression and response to treatment in patients with B-cell lymphomas.

Why is this test IgVH Gene Mutation Test taken?

The IgVH Gene Mutation Test is taken to determine the level of mutation in the immunoglobulin heavy chain variable region (IgVH) gene of B-cell lymphoma or leukemia cells. This test is important in predicting the prognosis of the disease and guiding treatment decisions.

Patients with a high level of IgVH gene mutations tend to have a better prognosis and respond well to certain treatments, while those with a low level of mutations may have a more aggressive disease course and may require more intensive therapy.

By analyzing the IgVH gene mutation status, healthcare providers can tailor treatment plans to individual patients, leading to more effective and personalized care.

No FAQs available.

Customer Google Rating